Yulan Sun

592 total citations
11 papers, 296 citations indexed

About

Yulan Sun is a scholar working on Molecular Biology, Oncology and Cancer Research. According to data from OpenAlex, Yulan Sun has authored 11 papers receiving a total of 296 indexed citations (citations by other indexed papers that have themselves been cited), including 4 papers in Molecular Biology, 3 papers in Oncology and 3 papers in Cancer Research. Recurrent topics in Yulan Sun's work include Cancer Immunotherapy and Biomarkers (2 papers), Lung Cancer Treatments and Mutations (2 papers) and Sesquiterpenes and Asteraceae Studies (2 papers). Yulan Sun is often cited by papers focused on Cancer Immunotherapy and Biomarkers (2 papers), Lung Cancer Treatments and Mutations (2 papers) and Sesquiterpenes and Asteraceae Studies (2 papers). Yulan Sun collaborates with scholars based in United States, China and Chile. Yulan Sun's co-authors include Daret K. St. Clair, William H. St. Clair, Peter A. Crooks, Yong Xu, Vivek M. Rangnekar, Graham Warren, Fang Fang, Fang Fang, Terry D. Oberley and Sajni Josson and has published in prestigious journals such as Cancer Research, Molecular Cancer Therapeutics and BMC Cancer.

In The Last Decade

Yulan Sun

9 papers receiving 289 citations

Peers

Countries citing papers authored by Yulan Sun

Since Specialization

Citations

This map shows the geographic impact of Yulan Sun's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yulan Sun with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yulan Sun more than expected).

Fields of papers citing papers by Yulan Sun

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yulan Sun. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yulan Sun. The network helps show where Yulan Sun may publish in the future.

Co-authorship network of co-authors of Yulan Sun

This figure shows the co-authorship network connecting the top 25 collaborators of Yulan Sun. A scholar is included among the top collaborators of Yulan Sun based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yulan Sun. Yulan Sun is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

11 of 11 papers shown

#	Work	Indexed citations
1	1328 SSGJ-707, a PD-1/VEGF bispecific antibody, combined with platinum-based chemotherapy in first-line treatment of advanced non-small cell lung cancer (NSCLC): Results from a phase 2 study 2025 ·Lin Wu, Haipeng Xu, Yulan Sun, (unknown), Siyuan Huang, (unknown), Yan Yu, Feng Ye, Dongqing Lv, (unknown), (unknown), Tao Xu, Xingxiang Pu, Xiang Li, Ruoyu Wang, Laiyu Liu, (unknown), Anwen Liu, (unknown), (unknown)	0
2	Strong PD-L1 affect clinical outcomes in advanced NSCLC treated with third-generation EGFR-TKIs 2024 ·Future Oncology ·(unknown), (unknown), (unknown), (unknown), Yaru Tian, (unknown), Hui Zhu, Yulan Sun	2
3	Evaluación docente en el mundo 2024 ·Jorge Manzi, Yulan Sun, (unknown)	0
4	Immune checkpoint inhibitor (ICI)-based treatment beyond progression with prior immunotherapy in patients with driver-gene negative advanced non-small cell lung cancer 2024 ·BMC Cancer ·Min Wang, (unknown), Feihu Chen, (unknown), Yulan Sun	4
5	CEOs' knowledge integration， entrepreneurship, and corporate innovation: Evidence for China 2023 ·International Review of Financial Analysis ·(unknown), (unknown), Yulan Sun, (unknown)	10
6	Teacher Evaluation Around the World 2022 ·Jorge Manzi, Yulan Sun, (unknown)	1
7	A NADPH Oxidase–Dependent Redox Signaling Pathway Mediates the Selective Radiosensitization Effect of Parthenolide in Prostate Cancer Cells 2010 ·Cancer Research ·Yulan Sun, Daret K. St. Clair, Yong Xu, Peter A. Crooks, William H. St. Clair	117
8	RelB-Dependent Differential Radiosensitization Effect of STI571 on Prostate Cancer Cells 2010 ·Molecular Cancer Therapeutics ·Yong Xu, Fang Fang, Yulan Sun, Daret K. St. Clair, William H. St. Clair	20
9	The effects of amitrole on thyroglobulin and iodide uptake in FRTL-5 cells 2010 ·Toxicology and Industrial Health ·(unknown), Yulan Sun, Lishi Zhang	5
10	RelB Enhances Prostate Cancer Growth: Implications for the Role of the Nuclear Factor-κB Alternative Pathway in Tumorigenicity 2009 ·Cancer Research ·Yong Xu, Sajni Josson, Fang Fang, Terry D. Oberley, Daret K. St. Clair, X. Steven Wan, Yulan Sun, Vasudevan Bakthavatchalu, (unknown), William H. St. Clair	66
11	The radiosensitization effect of parthenolide in prostate cancer cells is mediated by nuclear factor-κB inhibition and enhanced by the presence of PTEN 2007 ·Molecular Cancer Therapeutics ·Yulan Sun, Daret K. St. Clair, Fang Fang, Graham Warren, Vivek M. Rangnekar, Peter A. Crooks, William H. St. Clair	71

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact